PMID- 31410178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 18
IP  - 3
DP  - 2019 Sep
TI  - Clinicopathological and biological analysis of PIK3CA mutation and amplification 
      in cervical carcinomas.
PG  - 2278-2284
LID - 10.3892/etm.2019.7771 [doi]
AB  - The aim of the present study was to evaluate the mutation and amplification 
      status of the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
      (PIK3CA) gene, as well as the association with clinicopathological 
      characteristics and prognosis, in Japanese patients with cervical cancer. 
      Fluorescence in situ hybridization and polymerase chain reaction were performed 
      to assess PIK3CA gene amplification and mutation. The inhibitors temsirolimus and 
      NVP-BEZ235 were used to inactivate the phosphatidylinositide 3-kinase (PI3K)/AKT 
      serine/threonine kinase (AKT)/mechanistic target of rapamycin kinase (mTOR) 
      pathway to clarify the roles of PI3K/AKT activation in cervical carcinoma cells 
      harboring associated mutations. Four somatic point mutations (4/71, 5.6%) were 
      found in exon 20 in cervical squamous cell carcinoma samples, whereas three 
      (3/53, 5.7%) were found in exon 9 in cervical adeno/adenosquamous cell carcinoma 
      samples. Amplification of PIK3CA was also observed in this study and 
      amplification was more commonly found in adeno/adenosquamous carcinomas than in 
      cervical squamous cell carcinomas (20.7 vs. 1.4%, respectively, P=0.0003). No 
      significant correlation was obesrved between PIK3CA amplification and progression 
      free survival (P=0.7576) or overall survival (P=0.8859). Moreover, no association 
      between PIK3CA mutation and sensitivity to PI3K/AKT/mTOR inhibitors was observed 
      in cervical carcinoma cells. These results suggest that in Japanese patients with 
      cervical cancer, PIK3CA mutation and amplification cannot act as biomarkers for 
      individualized molecular targeted therapy.
FAU - Razia, Sultana
AU  - Razia S
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Nakayama, Kentaro
AU  - Nakayama K
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Nakamura, Kohei
AU  - Nakamura K
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Ishibashi, Tomoka
AU  - Ishibashi T
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Ishikawa, Masako
AU  - Ishikawa M
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Minamoto, Toshiko
AU  - Minamoto T
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Iida, Kouji
AU  - Iida K
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
FAU - Otsuki, Yoshiro
AU  - Otsuki Y
AD  - Department of Pathology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka 
      430-8558, Japan.
FAU - Nakayama, Satoru
AU  - Nakayama S
AD  - Department of Obstetrics and Gynecology, Seirei Hamamatsu General Hospital, 
      Hamamatsu, Shizuoka 430-8558, Japan.
FAU - Ishikawa, Noriyoshi
AU  - Ishikawa N
AD  - Department of Organ Pathology, Shimane University School of Medicine, Izumo, 
      Shimane 693-8501, Japan.
FAU - Kyo, Satoru
AU  - Kyo S
AD  - Department of Obstetrics and Gynecology, Shimane University School of Medicine, 
      Izumo, Shimane 693-8501, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190712
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6676184
OTO - NOTNLM
OT  - PIK3CA
OT  - adeno/adenosquamous cell carcinoma
OT  - cervical cancer
OT  - gene amplification
OT  - gene mutation
OT  - squamous cell carcinoma
EDAT- 2019/08/15 06:00
MHDA- 2019/08/15 06:01
PMCR- 2019/07/12
CRDT- 2019/08/15 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/07/19 00:00 [accepted]
PHST- 2019/08/15 06:00 [entrez]
PHST- 2019/08/15 06:00 [pubmed]
PHST- 2019/08/15 06:01 [medline]
PHST- 2019/07/12 00:00 [pmc-release]
AID - ETM-0-0-7771 [pii]
AID - 10.3892/etm.2019.7771 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Sep;18(3):2278-2284. doi: 10.3892/etm.2019.7771. Epub 2019 Jul 
      12.